Drug Shortage Report for TEVA-IRBESARTAN HCTZ
| Report ID | 101725 |
| Drug Identification Number | 02330512 |
| Brand name | TEVA-IRBESARTAN HCTZ |
| Common or Proper name | IRBESARTAN/HCTZ 150/12.5MG TAB |
| Company Name | TEVA CANADA LIMITED |
| Market Status | MARKETED |
| Active Ingredient(s) | HYDROCHLOROTHIAZIDE IRBESARTAN |
| Strength(s) | 12.5MG 150MG |
| Dosage form(s) | TABLET |
| Route of administration | ORAL |
| Packaging size | 100 |
| ATC code | C09DA |
| ATC description | ANGIOTENSIN II ANTAGONISTS, COMBINATIONS |
| Reason for shortage | Disruption of the manufacture of the drug. |
| Anticipated start date | |
| Actual start date | 2019-12-18 |
| Estimated end date | 2021-09-30 |
| Actual end date | 2021-09-09 |
| Shortage status | Resolved |
| Updated date | 2021-09-10 |
| Company comments | Allocating 100% of Teva market share from July to October 2020. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 30 NOVOPHARM COURT TORONTO, ONTARIO CANADA M1B 2K9 |
| Company contact information |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v34 | 2021-09-10 | French | Compare |
| v33 | 2021-09-10 | English | Compare |
| v32 | 2021-07-22 | French | Compare |
| v31 | 2021-07-22 | English | Compare |
| v30 | 2021-05-06 | French | Compare |
| v29 | 2021-05-06 | English | Compare |
| v28 | 2021-02-11 | French | Compare |
| v27 | 2021-02-11 | French | Compare |
| v26 | 2021-02-11 | English | Compare |
| v25 | 2020-09-22 | French | Compare |
| v24 | 2020-09-22 | French | Compare |
| v23 | 2020-09-22 | English | Compare |
| v22 | 2020-07-14 | French | Compare |
| v21 | 2020-07-14 | English | Compare |
| v20 | 2020-06-18 | French | Compare |
| v19 | 2020-06-18 | English | Compare |
| v18 | 2020-05-14 | French | Compare |
| v17 | 2020-05-14 | English | Compare |
| v16 | 2020-05-08 | French | Compare |
| v15 | 2020-05-08 | English | Compare |